Fortrea Holdings Inc. (FTRE) Fair Value 2026

FTRE · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.7 /10

32 fundamental signals · 7 models active

Value Trap Risk

WARN (54/100)

Quick Summary — As of 2026-08-28, Fortrea Holdings Inc. (FTRE) trades at $18.81, versus a $8.52 median fair value across its 7 active models — 54.7% below the current price. QOC: 5.7/10. Value Trap Risk: 54/100 (WARN). 7/13 models active. Within that set, the Bayesian DCF component alone returns $7.52.

Key Facts

Ticker
FTRE
Price
$18.81
Quality Score
5.7/10
Value Trap Risk
54/100
Models Active
7/13
Last Updated
Strength: 7 independent models provide multi-angle coverage
Risk: Value Trap score of 54 suggests caution despite apparent undervaluation

Is Fortrea Holdings Inc. (FTRE) Undervalued or Overvalued in 2026?

According to CirclFi’s 7-model valuation engine, Fortrea Holdings Inc. (FTRE) appears overvalued as of : the median of 7 independent fair value estimates is $8.52, 54.7% below the current price of $18.81. Estimates range from $6.78 to $20.28. FTRE scores 5.7/10 on fundamental quality and 54/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. FTRE’s -54.7% gap is wider than that market norm, and the Biotechnology sector median is -64.7%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Fortrea Holdings Inc. Stock in 2026? →

What Fair Value Does Each Model Give FTRE?

7 Intrinsic Value Models vs. Current Price ($18.81)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $7.52 -60.0%
Ensemble · Medium Conviction
 $8.79 -53.3%
Intrinsic · High Conviction
 $8.52 -54.7%
Unlock the Full Matrix

Access 4 additional models including PWERM, Regime Cross-Sectional, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 7 Models →

Cancel anytime · No contracts · Instant access

What Is FTRE's Fair Value Range?

Spread across 7 independent models · $6.78 to $20.28

CirclFi's 7 active models place Fortrea Holdings Inc. (FTRE) between $6.78 and $20.28 per share, a spread of 158% of the median. The median of that range — $8.52 — is the fair value CirclFi publishes for FTRE, against a current price of $18.81.

Low · Regime CrossHigh · PWERM
$6.78median $8.52$20.28
Where the range comes from
Most bearish modelRegime Cross-Sectional$6.78
Most bullish modelPWERM$20.28
Model agreement1 bullish · 6 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for FTRE. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on FTRE, not a CirclFi price target. How each model works →

What Is Fortrea Holdings Inc. (FTRE) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Fortrea Holdings Inc.'s intrinsic value is estimated at $8.52, suggesting the stock is overvalued at its current price of $18.81. With 6 out of 7 models flagging downside (-54.7% vs price), the market may be pricing in unsustainable growth. Model dispersion is worth noting: PWERM targets $20.28 (+7.8%), versus Regime Cross at $6.78 (-63.9%). This +71.8% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About FTRE?

7 of 13 models are currently active for FTRE. Of these, 1 model suggests upside while 6 models suggest overvaluation. Taken together, their median fair value for FTRE is $8.52 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $7.52 on its own, implying -60.0% downside from the current price. See which stocks rank higher →

How Does FTRE Rank in Biotechnology?

Among 625 Biotechnology stocks, FTRE ranks #190 by Quality of Company score. CirclFi's QOC score of 5.7/10 evaluates 32 fundamental signals. A score of 5.7 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

Within the Biotechnology space, Fortrea Holdings Inc. competes in an environment where pipeline depth and stage distribution often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is FTRE a Value Trap?

CirclFi's Value Trap algorithm assigns FTRE a score of 54/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

7 of 13 models are active for Fortrea Holdings Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Fortrea Holdings Inc. is rated at 5.7/10. This solid-tier score maintains reasonable quality metrics with some areas for improvement.

The gap between the most bullish and bearish model spans +71.8% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every FTRE valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across FTRE's 7 active models, average confidence is 42%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Fortrea Holdings Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

AAPGAscentage Pharma Group InternatQOC 5.7CGONCG Oncology, Inc.QOC 5.7OTLCOncotelic Therapeutics, Inc.QOC 5.7IMAImageneBio, Inc.QOC 5.7ENTXEntera Bio Ltd.QOC 5.7WHWKWhitehawk Therapeutics, Inc.QOC 5.7AVXLAnavex Life Sciences Corp.QOC 4.9SANASana Biotechnology, Inc.QOC 4.2GYREGyre Therapeutics, Inc.QOC 7.6EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: AAPG · CGON · OTLC · IMA · ENTX · WHWK · AVXL · SANA · GYRE · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to FTRE?

7 companies across all industries closest to FTRE’s Quality of Company score of 5.7/10.

VRNOVerano Holdings Corp.QOC 5.7FLZHFlash Sports & Media Holdings, Inc.QOC 5.7GFLTGenFlat Holdings, Inc.QOC 5.7RDNWRideNow Group, Inc.QOC 5.7CARVCarver Bancorp, Inc.QOC 5.7STFSStar Fashion Culture Holdings LimitedQOC 5.7NVDANVIDIA CorporationQOC 10.0

Read investment analysis: VRNO · FLZH · GFLT · RDNW · CARV · STFS · NVDA

Where Does FTRE Sit in CirclFi's Biotechnology Rankings?

FTRE is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Fortrea Holdings Inc.’s Valuation?

What is Fortrea Holdings Inc.'s intrinsic value in 2026?

CirclFi puts Fortrea Holdings Inc. (FTRE)'s intrinsic value at $8.52 — the median of 7 independent model estimates as of 2026-08-28, ranging from $6.78 to $20.28. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $7.52 on its own. The Quality of Company score is 5.7/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is FTRE overvalued or undervalued right now?

At $18.81, 1 of 7 active models suggest FTRE may be undervalued, while 6 indicate potential overvaluation. The median of all 7 fair value estimates is $8.52, 54.7% below the current price of $18.81 — a consensus view that FTRE is overvalued. The assessment depends on which methodology best fits Fortrea Holdings Inc.'s business model in Biotechnology.

What does a Quality of Company score of 5.7 mean for FTRE?

Fortrea Holdings Inc.'s QOC of 5.7/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on FTRE?

CirclFi analyzes FTRE with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 7 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on FTRE?

Of the 7 models currently active on FTRE, PWERM is the most bullish at $20.28 per share, and Regime Cross-Sectional is the most bearish at $6.78. CirclFi's published fair value for FTRE is the median of that range, $8.52, not either extreme. The gap between the two ends equals 158% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is FTRE a value trap in 2026?

Fortrea Holdings Inc.'s Value Trap score is 54/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries.

Cite this analysis — “According to CirclFi’s 7-model valuation engine, Fortrea Holdings Inc. (FTRE) has a median fair value of $8.52 — 54.7% below the current price of $18.81 — as of 2026-08-28.” Source: circlfi.com/stock/FTRE/ · Methodology
Primary sources for this FTRE valuation
  • Financial statements: Fortrea Holdings Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001965040) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for FTRE as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 7 mathematical frameworks give you clarity on FTRE.

Unlock All 7 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

4 models hidden for FTRE Unlock All 7 — $39/mo